Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report released on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

GLMD stock opened at $1.84 on Tuesday. Galmed Pharmaceuticals has a 1 year low of $1.75 and a 1 year high of $23.80. The company has a market cap of $1.19 million, a P/E ratio of -0.11 and a beta of 0.66. The firm has a 50-day moving average of $2.74 and a 200 day moving average of $3.55.

Hedge Funds Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.